A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice

References

• Abdala N, Carney JM, Durante AJ et al. Estimating the prevalence of syringe-borne and sexually transmitted diseases among injection drug users in St Petersburg, Russia. Int. J. STD AIDS 14(10), 697–703 (2003).
   PubMed Web of Science ®Google Scholar
• Kelly JA, Amirkhanian YA. The newest epidemic: a review of HIV/AIDS in Central and Eastern Europe. Int. J. STD AIDS 14(6), 361–371 (2003).
   PubMed Web of Science ®Google Scholar
• Caiaffa WT, Proietti FA, Carneiro-Proietti AB et al.; Epidemiological Study of Injection Drug Users in Brazil (AjUDE-Brasil Project). The dynamics of the human immunodeficiency virus epidemics in the south of Brazil: increasing role of injection drug users. Clin. Infect. Dis. 37(Suppl. 5), S376–S381 (2003).
   PubMed Web of Science ®Google Scholar
• Zhang C, Yang R, Xia X et al. High prevalence of HIV-1 and hepatitis C virus coinfection among injection drug users in the southeastern region of Yunnan, China. J. Acquir. Immune Defic. Syndr. 29(2), 191–196 (2002).
   PubMed Web of Science ®Google Scholar
• Averhoff FM, Glass N, Holtzman D. Global burden of hepatitis C: considerations for healthcare providers in the United States. Clin. Infect. Dis. 55(Suppl. 1), S10–S15 (2012).
   PubMed Web of Science ®Google Scholar
• Morineau G, Bollen LJ, Syafitri RI, Nurjannah N, Mustikawati DE, Magnani R. HIV prevalence and risk behaviours among injecting drug users in six Indonesian cities implications for future HIV prevention programs. Harm Reduct. J. 9(1), 37 (2012).
   PubMed Web of Science ®Google Scholar
• United Nations Office on Drugs and Crime. World Drug Report E.12.XI.1 United Nations Office on Drugs and Crime, Vienna, Austria (2012).
   Google Scholar
• Nelson PK, Mathers BM, Cowie B et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 378(9791), 571–583 (2011).
   PubMed Web of Science ®Google Scholar
• Hart GJ, Sonnex C, Petherick A, Johnson AM, Feinmann C, Adler MW. Risk behaviours for HIV infection among injecting drug users attending a drug dependency clinic. BMJ 298(6680), 1081–1083 (1989).
   PubMed Web of Science ®Google Scholar
• Dolan K, Hall W, Wodak A. Methadone maintenance reduces injecting in prison. BMJ 312(7039), 1162 (1996).
   PubMed Web of Science ®Google Scholar
• Donny EC, Walsh SL, Bigelow GE, Eissenberg T, Stitzer ML. High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid-dependent humans. Psychopharmacology (Berl.) 161(2), 202–212 (2002).
   PubMed Web of Science ®Google Scholar
• Fiellin DA, O’Connor PG. Clinical practice. Office-based treatment of opioid-dependent patients. N. Engl. J. Med. 347(11), 817–823 (2002).
   PubMed Web of Science ®Google Scholar
• Bruce RD. Methadone as HIV prevention: high volume methadone sites to decrease HIV incidence rates in resource limited settings. Int. J. Drug Policy 21(2), 122–124 (2010).
   PubMed Web of Science ®Google Scholar
• Altice FL, Kamarulzaman A, Soriano VV, Schechter M, Friedland GH. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet 376(9738), 367–387 (2010).
   PubMed Web of Science ®Google Scholar
• Friedland G, Vlahov D. Integration of buprenorphine for substance-abuse treatment by HIV care providers. J. Acquir. Immune Defic. Syndr. 56(Suppl. 1), S1–S2 (2011).
   PubMed Web of Science ®Google Scholar
• Bruce RD, Eiserman J, Acosta A, Gote C, Lim JK, Altice FL. Developing a modified directly observed therapy intervention for hepatitis C treatment in a methadone maintenance program: implications for program replication. Am. J. Drug Alcohol Abuse 38(3), 206–212 (2012).
   PubMed Web of Science ®Google Scholar
• Cohen MS, Chen YQ, McCauley M et al.; HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N. Engl. J. Med. 365(6), 493–505 (2011).
   PubMed Web of Science ®Google Scholar
• Lee HY, Li JH, Wu LT, Wu JS, Yen CF, Tang HP. Survey of methadone–drug interactions among patients of methadone maintenance treatment program in Taiwan. Subst. Abuse Treat. Prev. Pol. 7, 11 (2012).
   PubMedGoogle Scholar
• Bruce RD, Altice FL, Gourevitch MN, Friedland GH. Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice. J. Acquir. Immune Defic. Syndr. 41(5), 563–572 (2006).
   PubMed Web of Science ®Google Scholar
• Gonzalez F, Coughtrie M, Tukey RH. Drug metabolism. In: Goodman & Gilman’s The Pharmacological Basis of Therapeutics. Goodman LS, Brunton LL, Chabner B, Knollmann BC (Eds). McGraw-Hill, NY, USA, 2084 (2011).
   Google Scholar
• Brown SM, Campbell SD, Crafford A, Regina KJ, Holtzman MJ, Kharasch ED. P-glycoprotein is a major determinant of norbuprenorphine brain exposure and antinociception. J. Pharmacol. Exp. Ther. 343(1), 53–61 (2012).
   PubMed Web of Science ®Google Scholar
• Brown SM, Holtzman M, Kim T, Kharasch ED. Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active. Anesthesiology 115(6), 1251–1260 (2011).
   PubMed Web of Science ®Google Scholar
• Tournier N, Chevillard L, Megarbane B, Pirnay S, Scherrmann JM, Declèves X. Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). Int. J. Neuropsychopharmacol. 13(7), 905–915 (2010).
   PubMed Web of Science ®Google Scholar
• Alhaddad H, Cisternino S, Declèves X et al. Respiratory toxicity of buprenorphine results from the blockage of P-glycoprotein-mediated efflux of norbuprenorphine at the blood-brain barrier in mice. Crit. Care Med. 40(12), 3215–3223 (2012).
   PubMed Web of Science ®Google Scholar
• Yassen A, Kan J, Olofsen E, Suidgeest E, Dahan A, Danhof M. Pharmacokinetic–pharmacodynamic modeling of the respiratory depressant effect of norbuprenorphine in rats. J. Pharmacol. Exp. Ther. 321(2), 598–607 (2007).
   PubMed Web of Science ®Google Scholar
• Mégarbane B, Marie N, Pirnay S et al. Buprenorphine is protective against the depressive effects of norbuprenorphine on ventilation. Toxicol. Appl. Pharmacol. 212(3), 256–267 (2006).
   PubMed Web of Science ®Google Scholar
• Moody DE, Fang WB, Morrison J, McCance-Katz E. Gender differences in pharmacokinetics of maintenance dosed buprenorphine. Drug Alcohol Depend. 118(2–3), 479–483 (2011).
   PubMed Web of Science ®Google Scholar
• Inturrisi CE, Verebely K. Disposition of methadone in man after a single oral dose. Clin. Pharmacol. Ther. 13(6), 923–930 (1972).
   PubMed Web of Science ®Google Scholar
• Scott CC, Robbins EB, Chen KK. Pharmacologic comparison of the optical isomers of methadon. J. Pharmacol. Exp. Ther. 93(3), 282–286 (1948).
   PubMed Web of Science ®Google Scholar
• Kristensen K, Christensen CB, Christrup LL. The μ1, μ2, δ, κ opioid receptor binding profiles of methadone stereoisomers and morphine. Life Sci. 56(2), PL45–PL50 (1995).
   PubMed Web of Science ®Google Scholar
• Pohland A, Boaz HE, Sullivan HR. Synthesis and identification of metabolites resulting from the biotransformation of dl-methadone in man and in the rat. J. Med. Chem. 14(3), 194–197 (1971).
   PubMed Web of Science ®Google Scholar
• Pert CB, Snyder SH. Opiate receptor: demonstration in nervous tissue. Science 179(4077), 1011–1014 (1973).
   PubMed Web of Science ®Google Scholar
• Horng JS, Smits SE, Wong DT. The binding of the optical isomers of methadone, α-methadol, α-acetylmethadol and their N-demethylated derivatives to the opiate receptors of rat brain. Res. Commun. Chem. Pathol. Pharmacol. 14(4), 621–629 (1976).
   PubMedGoogle Scholar
• Lötsch J, Skarke C, Wieting J et al. Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. Clin. Pharmacol. Ther. 79(1), 72–89 (2006).
   PubMed Web of Science ®Google Scholar
• Lin C, Somberg T, Molnar J, Somberg J. The effects of chiral isolates of methadone on the cardiac potassium channel IKr. Cardiology 113(1), 59–65 (2009).
   PubMed Web of Science ®Google Scholar
• Eap CB, Crettol S, Rougier JS et al. Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clin. Pharmacol. Ther. 81(5), 719–728 (2007).
   PubMed Web of Science ®Google Scholar
• Wang JS, DeVane CL. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro. Drug Metab. Dispos. 31(6), 742–747 (2003).
   PubMed Web of Science ®Google Scholar
• Moody DE, Alburges ME, Parker RJ, Collins JM, Strong JM. The involvement of cytochrome P450 3A4 in the N-demethylation of L-α-acetylmethadol (LAAM), norLAAM, and methadone. Drug Metab. Dispos. 25(12), 1347–1353 (1997).
   PubMed Web of Science ®Google Scholar
• Gerber JG, Rhodes RJ, Gal J. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality 16(1), 36–44 (2004).
   PubMed Web of Science ®Google Scholar
• Kharasch ED, Hoffer C, Whittington D, Sheffels P. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin. Pharmacol. Ther. 76(3), 250–269 (2004).
   PubMed Web of Science ®Google Scholar
• Totah RA, Sheffels P, Roberts T, Whittington D, Thummel K, Kharasch ED. Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology 108(3), 363–374 (2008).
   PubMed Web of Science ®Google Scholar
• Chang Y, Fang WB, Lin SN, Moody DE. Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: a reconciliation. Basic Clin. Pharmacol. Toxicol. 108(1), 55–62 (2011).
   PubMed Web of Science ®Google Scholar
• Iribarne C, Berthou F, Baird S et al. Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem. Res. Toxicol. 9(2), 365–373 (1996).
   PubMed Web of Science ®Google Scholar
• Begré S, von Bardeleben U, Ladewig D et al. Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers. J. Clin. Psychopharmacol. 22(2), 211–215 (2002).
   PubMed Web of Science ®Google Scholar
• Kharasch ED, Bedynek PS, Hoffer C, Walker A, Whittington D. Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A). Anesthesiology 116(2), 432–447 (2012).
   PubMed Web of Science ®Google Scholar
• Kharasch ED, Whittington D, Ensign D et al. Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther. 91(4), 673–684 (2012).
   PubMed Web of Science ®Google Scholar
• Foster DJ, Somogyi AA, Bochner F. Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4. Br. J. Clin. Pharmacol. 47(4), 403–412 (1999).
   PubMed Web of Science ®Google Scholar
• Prost F, Thormann W. Capillary electrophoresis to assess drug metabolism induced in vitro using single CYP450 enzymes (Supersomes): application to the chiral metabolism of mephenytoin and methadone. Electrophoresis 24(15), 2577–2587 (2003).
   PubMed Web of Science ®Google Scholar
• Shinderman M, Maxwell S, Brawand-Amey M, Golay KP, Baumann P, Eap CB. Cytochrome P4503A4 metabolic activity, methadone blood concentrations, and methadone doses. Drug Alcohol Depend. 69(2), 205–211 (2003).
   PubMed Web of Science ®Google Scholar
• Shiran MR, Lennard MS, Iqbal MZ et al. Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment. Br. J. Clin. Pharmacol. 67(1), 29–37 (2009).
   PubMed Web of Science ®Google Scholar
• Crettol S, Déglon JJ, Besson J et al. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin. Pharmacol. Ther. 80(6), 668–681 (2006).
   PubMed Web of Science ®Google Scholar
• Wang SC, Ho IK, Tsou HH et al. CYP2B6 polymorphisms influence the plasma concentration and clearance of the methadone S-enantiomer. J. Clin. Psychopharmacol. 31(4), 463–469 (2011).
   PubMed Web of Science ®Google Scholar
• Crettol S, Déglon JJ, Besson J et al. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin. Pharmacol. Ther. 78(6), 593–604 (2005).
   PubMed Web of Science ®Google Scholar
• Dobrinas M, Crettol S, Oneda B et al. Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels: a CYP2B6 gene resequencing study. Pharmacogenet. Genomics 23(2), 84–93 (2013).
   PubMed Web of Science ®Google Scholar
• Hung CC, Chiou MH, Huang BH et al. Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients. Pharmacogenomics 12(11), 1525–1533 (2011).
   PubMed Web of Science ®Google Scholar
• Fonseca F, De La Torre R, Diaz L et al. Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response. PLoS One 6(5), e19527 (2011).
   Google Scholar
• Levran O, Peles E, Hamon S, Randesi M, Adelson M, Kreek MJ. CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction. Addict. Biol. doi:10.1111/j.1369-1600.2011.00349.x (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Bunten H, Liang WJ, Pounder D, Seneviratne C, Osselton MD. CYP2B6 and OPRM1 gene variations predict methadone-related deaths. Addict. Biol. 16(1), 142–144 (2011).
   PubMed Web of Science ®Google Scholar
• Stringer J, Welsh C, Tommasello A. Methadone-associated Q-T interval prolongation and torsades de pointes. Am. J. Health Syst. Pharm. 66(9), 825–833 (2009).
   PubMed Web of Science ®Google Scholar
• Eap CB, Broly F, Mino A et al. Cytochrome P450 2D6 genotype and methadone steady-state concentrations. J. Clin. Psychopharmacol. 21(2), 229–234 (2001).
   PubMed Web of Science ®Google Scholar
• Kharasch ED, Walker A, Whittington D, Hoffer C, Bedynek PS. Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity. Drug Alcohol Depend. 101(3), 158–168 (2009).
   PubMed Web of Science ®Google Scholar
• Kharasch ED, Bedynek PS, Park S, Whittington D, Walker A, Hoffer C. Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance. Clin. Pharmacol. Ther. 84(4), 497–505 (2008).
   PubMed Web of Science ®Google Scholar
• Kirby BJ, Collier AC, Kharasch ED et al. Complex drug interactions of HIV protease inhibitors 2: in vivo induction and in vitro to in vivo correlation of induction of cytochrome P450 1A2, 2B6, and 2C9 by ritonavir or nelfinavir. Drug Metab. Dispos. 39(12), 2329–2337 (2011).
   PubMed Web of Science ®Google Scholar
• Verebely K, Volavka J, Mulé S, Resnick R. Methadone in man: pharmacokinetic and excretion studies in acute and chronic treatment. Clin. Pharmacol. Ther. 18(2), 180–190 (1975).
   PubMed Web of Science ®Google Scholar
• Gelston EA, Coller JK, Lopatko OV et al. Methadone inhibits CYP2D6 and UGT2B7/2B4 in vivo: a study using codeine in methadone- and buprenorphine-maintained subjects. Br. J. Clin. Pharmacol. 73(5), 786–794 (2012).
   PubMed Web of Science ®Google Scholar
• Lu WJ, Bies R, Kamden LK, Desta Z, Flockhart DA. Methadone: a substrate and mechanism-based inhibitor of CYP19 (aromatase). Drug Metab. Dispos. 38(8), 1308–1313 (2010).
   PubMed Web of Science ®Google Scholar
• Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin. Pharmacokinet. 41(14), 1153–1193 (2002).
   PubMed Web of Science ®Google Scholar
• Levran O, O’Hara K, Peles E et al. ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. Hum. Mol. Genet. 17(14), 2219–2227 (2008).
   PubMed Web of Science ®Google Scholar
• Cone EJ, Gorodetzky CW, Yousefnejad D, Buchwald WF, Johnson RE. The metabolism and excretion of buprenorphine in humans. Drug Metab. Dispos. 12(5), 577–581 (1984).
   PubMed Web of Science ®Google Scholar
• Iribarne C, Picart D, Dréano Y, Bail JP, Berthou F. Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes. Life Sci. 60(22), 1953–1964 (1997).
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Yamamoto T, Chiba K et al. Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4. Drug Metab. Dispos. 26(8), 818–821 (1998).
   PubMed Web of Science ®Google Scholar
• Moody DE, Slawson MH, Strain EC, Laycock JD, Spanbauer AC, Foltz RL. A liquid chromatographic–electrospray ionization–tandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine, and a coformulant, naloxone, that is suitable for in vivo and in vitro metabolism studies. Anal. Biochem. 306(1), 31–39 (2002).
   PubMed Web of Science ®Google Scholar
• Picard N, Cresteil T, Djebli N, Marquet P. In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. Drug Metab. Dispos. 33(5), 689–695 (2005).
   PubMed Web of Science ®Google Scholar
• Chang Y, Moody DE, McCance-Katz EF. Novel metabolites of buprenorphine detected in human liver microsomes and human urine. Drug Metab. Dispos. 34(3), 440–448 (2006).
   PubMed Web of Science ®Google Scholar
• Moody DE, Chang Y, Huang W, McCance-Katz EF. The in vivo response of novel buprenorphine metabolites, M1 and M3, to antiretroviral inducers and inhibitors of buprenorphine metabolism. Basic Clin. Pharmacol. Toxicol. 105(3), 211–215 (2009).
   PubMed Web of Science ®Google Scholar
• Chang Y, Moody DE. Glucuronidation of buprenorphine and norbuprenorphine by human liver microsomes and UDP-glucuronosyltransferases. Drug Metab. Lett. 3(2), 101–107 (2009).
   PubMedGoogle Scholar
• Rouguieg K, Picard N, Sauvage FL, Gaulier JM, Marquet P. Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes. Drug Metab. Dispos. 38(1), 40–45 (2010).
   PubMed Web of Science ®Google Scholar
• Huang W, Moody DE, McCance-Katz EF. The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography–electrospray ionization–tandem mass spectrometry. Ther. Drug Monit. 28(2), 245–251 (2006).
   PubMed Web of Science ®Google Scholar
• Umehara K, Shimokawa Y, Miyamoto G. Inhibition of human drug metabolizing cytochrome P450 by buprenorphine. Biol. Pharm. Bull. 25(5), 682–685 (2002).
   PubMed Web of Science ®Google Scholar
• Zhang W, Ramamoorthy Y, Tyndale RF, Sellers EM. Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. Drug Metab. Dispos. 31(6), 768–772 (2003).
   PubMed Web of Science ®Google Scholar
• Ohtani M, Kotaki H, Sawada Y, Iga T. Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic–pharmacodynamic modeling. J. Pharmacol. Exp. Ther. 272(2), 505–510 (1995).
   PubMed Web of Science ®Google Scholar
• Huang P, Kehner GB, Cowan A, Liu-Chen LY. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J. Pharmacol. Exp. Ther. 297(2), 688–695 (2001).
   PubMed Web of Science ®Google Scholar
• Sommadossi JP. Cellular nucleoside pharmacokinetics and pharmacology: a potentially important determinant of antiretroviral efficacy. AIDS 12(Suppl. 3), S1–S8 (1998).
   PubMed Web of Science ®Google Scholar
• Beach JW. Chemotherapeutic agents for human immunodeficiency virus infection: mechanism of action, pharmacokinetics, metabolism, and adverse reactions. Clin. Ther. 20(1), 2–25; discussion l (1998).
   PubMed Web of Science ®Google Scholar
• Veal GJ, Back DJ. Metabolism of Zidovudine. Gen. Pharmacol. 26(7), 1469–1475 (1995).
   PubMedGoogle Scholar
• Deeks SG, Barditch-Crovo P, Lietman PS et al. Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. Antimicrob. Agents Chemother. 42(9), 2380–2384 (1998).
   PubMed Web of Science ®Google Scholar
• Heald AE, Hsyu PH, Yuen GJ, Robinson P, Mydlow P, Bartlett JA. Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction. Antimicrob. Agents Chemother. 40(6), 1514–1519 (1996).
   PubMed Web of Science ®Google Scholar
• de Souza J, Benet LZ, Huang Y, Storpirtis S. Comparison of bidirectional lamivudine and zidovudine transport using MDCK, MDCK-MDR1, and Caco-2 cell monolayers. J. Pharm. Sci. 98(11), 4413–4419 (2009).
   PubMed Web of Science ®Google Scholar
• Storch CH, Theile D, Lindenmaier H, Haefeli WE, Weiss J. Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem. Pharmacol. 73(10), 1573–1581 (2007).
   PubMed Web of Science ®Google Scholar
• Murphy RL, Sommadossi JP, Lamson M, Hall DB, Myers M, Dusek A. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1. J. Infect. Dis. 179(5), 1116–1123 (1999).
   PubMed Web of Science ®Google Scholar
• Lamson M, Macgregor T, Riska P et al. Nevirapine induces both CYP3A4 and CYP2B6 metabolic pathways. Clin. Pharmacol. Therapeut. 65, 137 (1999).
   Google Scholar
• Erickson DA, Mather G, Trager WF, Levy RH, Keirns JJ. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab. Dispos. 27(12), 1488–1495 (1999).
   PubMed Web of Science ®Google Scholar
• Penzak SR, Kabuye G, Mugyenyi P et al. Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda. HIV Med. 8(2), 86–91 (2007).
   PubMed Web of Science ®Google Scholar
• Mouly S, Lown KS, Kornhauser D et al. Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin. Pharmacol. Ther. 72(1), 1–9 (2002).
   PubMed Web of Science ®Google Scholar
• Robertson SM, Maldarelli F, Natarajan V, Formentini E, Alfaro RM, Penzak SR. Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects. J. Acquir. Immune Defic. Syndr. 49(5), 513–519 (2008).
   PubMed Web of Science ®Google Scholar
• Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J. Pharmacol. Exp. Ther. 306(1), 287–300 (2003).
   PubMed Web of Science ®Google Scholar
• Hansten PD. Drug Interactions. Applied Therapeutics, Inc., Vancouver, WA, USA (1995).
   Google Scholar
• von Moltke LL, Greenblatt DJ, Granda BW et al. Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. J. Clin. Pharmacol. 41(1), 85–91 (2001).
   PubMed Web of Science ®Google Scholar
• Zhou S, Yung Chan S, Cher Goh B et al. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin. Pharmacokinet. 44(3), 279–304 (2005).
   PubMed Web of Science ®Google Scholar
• Schiller DS, Youssef-Bessler M. Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV. Clin. Ther. 31(4), 692–704 (2009).
   PubMed Web of Science ®Google Scholar
• Scholler-Gyure, Kakuda TN, Sekar V et al. Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers. Antivir. Ther. 12(5), 789–796 (2007).
   PubMed Web of Science ®Google Scholar
• Brown KC, Paul S, Kashuba AD. Drug interactions with new and investigational antiretrovirals. Clin. Pharmacokinet. 48(4), 211–241 (2009).
   PubMed Web of Science ®Google Scholar
• Crauwels HM, Kakuda TN. Drug interactions with new and investigational antiretrovirals. Clin. Pharmacokinet. 49(1), 67–68; author reply 68 (2010).
   PubMed Web of Science ®Google Scholar
• Vourvahis M, Gleave M, Nedderman AN et al. Excretion and metabolism of lersivirine (5-{[3,5-diethyl-1-(2-hydroxyethyl)(3,5-14C2)-1H-pyrazol-4-yl]oxy}benzene-1,3-dic arbonitrile), a next-generation non-nucleoside reverse transcriptase inhibitor, after administration of [14C]lersivirine to healthy volunteers. Drug Metab. Dispos. 38(5), 789–800 (2010).
   PubMed Web of Science ®Google Scholar
• Langdon G, Davis J, Layton G et al. Pharmacokinetic interactions of the next-generation NNRTI UK-453,061 with other antiretrovirals and assessment of safety and tolerability in healthy male subjects. Poster 763. Presented at: 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 3–6 February 2008.
   Google Scholar
• Clarke SM, Mulcahy FM, Tjia J et al. The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br. J. Clin. Pharmacol. 51(3), 213–217 (2001).
   PubMed Web of Science ®Google Scholar
• Clarke SM, Mulcahy FM, Tjia J et al. Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users. Clin. Infect. Dis. 33(9), 1595–1597 (2001).
   PubMed Web of Science ®Google Scholar
• McCance-Katz EF, Moody DE, Morse GD et al. Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine. Clin. Infect. Dis. 43(Suppl. 4), S224–S234 (2006).
   PubMed Web of Science ®Google Scholar
• McCance-Katz EF, Moody DE, Morse GD, Ma Q, Rainey PM. Lack of clinically significant drug interactions between nevirapine and buprenorphine. Am. J. Addict. 19(1), 30–37 (2010).
   PubMed Web of Science ®Google Scholar
• Kappelhoff BS, Crommentuyn KM, de Maat MM, Mulder JW, Huitema AD, Beijnen JH. Practical guidelines to interpret plasma concentrations of antiretroviral drugs. Clin. Pharmacokinet. 43(13), 845–853 (2004).
   PubMed Web of Science ®Google Scholar
• Flexner C. HIV-protease inhibitors. N. Engl. J. Med. 338(18), 1281–1292 (1998).
   PubMed Web of Science ®Google Scholar
• Decker CJ, Laitinen LM, Bridson GW, Raybuck SA, Tung RD, Chaturvedi PR. Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions. J. Pharm. Sci. 87(7), 803–807 (1998).
   PubMed Web of Science ®Google Scholar
• Rittweger M, Arastéh K. Clinical pharmacokinetics of darunavir. Clin. Pharmacokinet. 46(9), 739–756 (2007).
   PubMed Web of Science ®Google Scholar
• Yeni P. Tipranavir: a protease inhibitor from a new class with distinct antiviral activity. J. Acquir. Immune Defic. Syndr. 34(Suppl. 1), S91–S94 (2003).
   PubMed Web of Science ®Google Scholar
• Faragon JJ, Piliero PJ. Drug interactions associated with HAART: focus on treatments for addiction and recreational drugs. AIDS Read. 13(9), 433–434, 437–441, 446–450 (2003).
   PubMedGoogle Scholar
• Bierman WF, Scheffer GL, Schoonderwoerd A et al. Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but poor substrates, of ABC transporters in a broad panel of ABC transporter-overexpressing cell lines. J. Antimicrob. Chemother. 65(8), 1672–1680 (2010).
   PubMed Web of Science ®Google Scholar
• König SK, Herzog M, Theile D, Zembruski N, Haefeli WE, Weiss J. Impact of drug transporters on cellular resistance towards saquinavir and darunavir. J. Antimicrob. Chemother. 65(11), 2319–2328 (2010).
   PubMed Web of Science ®Google Scholar
• Kassahun K, McIntosh I, Cui D et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab. Dispos. 35(9), 1657–1663 (2007).
   PubMed Web of Science ®Google Scholar
• Iwamoto M, Wenning LA, Mistry GC et al. Atazanavir modestly increases plasma levels of raltegravir in healthy subjects. Clin. Infect. Dis. 47(1), 137–140 (2008).
   PubMed Web of Science ®Google Scholar
• Klibanov OM. Elvitegravir, an oral HIV integrase inhibitor, for the potential treatment of HIV infection. Curr. Opin. Investig. Drugs 10(2), 190–200 (2009).
   PubMed Web of Science ®Google Scholar
• Reese MJ, Savina PM, Generaux GT et al. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab. Dispos. 41(2), 353–361 (2013).
   PubMed Web of Science ®Google Scholar
• Walker DK, Abel S, Comby P, Muirhead GJ, Nedderman AN, Smith DA. Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. Drug Metab. Dispos. 33(4), 587–595 (2005).
   PubMed Web of Science ®Google Scholar
• Abel S, Russell D, Whitlock LA, Ridgway CE, Muirhead GJ. Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloestradiol/levonorgestrel in healthy volunteers. Br. J. Clin. Pharmacol. 65(Suppl. 1), 19–26 (2008).
   PubMed Web of Science ®Google Scholar
• Abel S, Jenkins TM, Whitlock LA, Ridgway CE, Muirhead GJ. Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br. J. Clin. Pharmacol. 65(Suppl. 1), 38–46 (2008).
   PubMed Web of Science ®Google Scholar
• Abel S, Russell D, Taylor-Worth RJ, Ridgway CE, Muirhead GJ. Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br. J. Clin. Pharmacol. 65(Suppl. 1), 27–37 (2008).
   PubMed Web of Science ®Google Scholar
• Kumar GN, Dykstra J, Roberts EM et al. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: a positive drug-drug interaction. Drug Metab. Dispos. 27(8), 902–908 (1999).
   PubMed Web of Science ®Google Scholar
• Mathias AA, German P, Murray BP et al. Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin. Pharmacol. Ther. 87(3), 322–329 (2010).
   PubMed Web of Science ®Google Scholar
• Bruce R, Winkle R, Custodio J et al. Pharmacotherapies of cobicistat-boosted elvitegravir administered in combination with methadone and buprenorphine/naloxone. Abstract A-1250. Presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 9–12 September 2012.
   Google Scholar
• Schwartz EL, Brechbühl AB, Kahl P, Miller MA, Selwyn PA, Friedland GH. Pharmacokinetic interactions of zidovudine and methadone in intravenous drug-using patients with HIV infection. J. Acquir. Immune Defic. Syndr. 5(6), 619–626 (1992).
   PubMed Web of Science ®Google Scholar
• McCance-Katz EF, Rainey PM, Jatlow P, Friedland G. Methadone effects on zidovudine disposition (AIDS Clinical Trials Group 262). J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 18(5), 435–443 (1998).
   PubMedGoogle Scholar
• McCance-Katz EF, Rainey PM, Friedland G, Kosten TR, Jatlow P. Effect of opioid dependence pharmacotherapies on zidovudine disposition. Am. J. Addict. 10(4), 296–307 (2001).
   PubMed Web of Science ®Google Scholar
• Rainey PM, Friedland GH, Snidow JW et al. The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects. Am. J. Addict. 11(1), 66–74 (2002).
   PubMed Web of Science ®Google Scholar
• Rainey PM, Friedland G, McCance-Katz EF et al. Interaction of methadone with didanosine and stavudine. J. Acquir. Immune Defic. Syndr. 24(3), 241–248 (2000).
   PubMed Web of Science ®Google Scholar
• Friedland G, Rainey P, Jatlow P, Andrews L, Damle B, McCance-Katz EF. Pharmacokinetics (PK) of didanosine (ddI) from encapsulated enteric coated bead formulation (EC) vs chewable tablet formulation in patients (pts) on chronic methadone therapy. Presented at: 14th International AIDS Conference. Barcelona, Spain, 7–12 July 2002.
   Google Scholar
• McDowell JA, Chittick GE, Ravitch JR, Polk RE, Kerkering TM, Stein DS. Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study. Antimicrob. Agents Chemother. 43(12), 2855–2861 (1999).
   PubMed Web of Science ®Google Scholar
• Yuen GJ, Weller S, Pakes GE. A review of the pharmacokinetics of abacavir. Clin. Pharmacokinet. 47(6), 351–371 (2008).
   PubMed Web of Science ®Google Scholar
• Sellers E, Lam R, Mcdowell J. The pharmacokinetics (PK) of abacavir (ABC) and methadone (M) following co-administration: CNAA 1012. Abstract 305. Presented at:39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 26–29 September 1999.
   Google Scholar
• Smith PF, Kearney BP, Liaw S et al. Effect of tenofovir disoproxil fumarate on the pharmacokinetics and pharmacodynamics of total, R-, and S-methadone. Pharmacotherapy 24(8), 970–977 (2004).
   PubMed Web of Science ®Google Scholar
• Fung HB, Stone EA, Piacenti FJ. Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection. Clin. Ther. 24(10), 1515–1548 (2002).
   PubMed Web of Science ®Google Scholar
• Altice FL, Friedland GH, Cooney EL. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS 13(8), 957–962 (1999).
   PubMed Web of Science ®Google Scholar
• Otero MJ, Fuertes A, Sánchez R, Luna G. Nevirapine-induced withdrawal symptoms in HIV patients on methadone maintenance programme: an alert. AIDS 13(8), 1004–1005 (1999).
   PubMed Web of Science ®Google Scholar
• Heelon MW, Meade LB. Methadone withdrawal when starting an antiretroviral regimen including nevirapine. Pharmacotherapy 19(4), 471–472 (1999).
   PubMed Web of Science ®Google Scholar
• Pinzani V, Faucherre V, Peyriere H, Blayac JP. Methadone withdrawal symptoms with nevirapine and efavirenz. Ann. Pharmacother. 34(3), 405–407 (2000).
   PubMed Web of Science ®Google Scholar
• Staszewski S, Haberl A, Gute P, Nisius G, Miller V, Carlebach A. Nevirapine/didanosine/lamivudine once daily in HIV-1-infected intravenous drug users. Antivir. Ther. (Lond.) 3(Suppl. 4), 55–56 (1998).
   PubMed Web of Science ®Google Scholar
• Stocker H, Kruse G, Kreckel P et al. Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 48(11), 4148–4153 (2004).
   PubMed Web of Science ®Google Scholar
• Clarke SM, Mulcahy FM. Efavirenz therapy in drug users. HIV Med. 1(Suppl 1), 15–17 (2000).
   PubMedGoogle Scholar
• Marzolini C, Troillet N, Telenti A, Baumann P, Decosterd LA, Eap CB. Efavirenz decreases methadone blood concentrations. AIDS 14(9), 1291–1292 (2000).
   PubMed Web of Science ®Google Scholar
• Tashima K, Bose T, Gormley J. The potential impact of efavirenz on methadone maintenance. Abstract P0552. Presented at: 9th European Congress of Clinical Microbiology and Infectious Diseases. Berlin, Germany, 21–24 March 1999.
   Google Scholar
• McCance-Katz EF, Rainey PM, Smith P et al. Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and delavirdine. Am. J. Addict. 15(1), 23–34 (2006).
   PubMed Web of Science ®Google Scholar
• Booker B, Smith P, Forrest A et al. Lack of effect on methadone (MET) on the pharmacokinetics (PK) of delavirdine (DLV) & N-delavirdine. Abstract A490. Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 16–19 December 2001.
   Google Scholar
• Schöller-Gyüre M, van den Brink W, Kakuda TN et al. Pharmacokinetic and pharmacodynamic study of the concomitant administration of methadone and TMC125 in HIV-negative volunteers. J. Clin. Pharmacol. 48(3), 322–329 (2008).
   PubMed Web of Science ®Google Scholar
• Crauwels H, Van Heeswijk RPG, Vandevoorde A et al. Pharmacokinetic interaction study between TMC278, a next-generation NNRTI, and methadone. Abstract WEPE0089. Presented at: XVIIIth International AIDS Conference. Vienna, Austria, 18–23 July 2010.
   Google Scholar
• Vourvahis M, Wang R, Gruener DM, Bruce RD, Haider S, Tawadrous M. Effect of lersivirine co-administration on pharmacokinetics of methadone in healthy volunteers. Drug Alcohol Depend. 126(1–2), 183–188 (2012).
   PubMed Web of Science ®Google Scholar
• McCance-Katz EF, Rainey PM, Friedland G, Jatlow P. The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients. Clin. Infect. Dis. 37(4), 476–482 (2003).
   PubMed Web of Science ®Google Scholar
• Cantilena L, Mccrea J, Blazes, D et al. Lack of pharmacokinetic interaction between indinavir and methadone. Clin. Pharmacol. Therapeut. 65(2), 135 (1999).
   Google Scholar
• McCance-Katz EF, Rainey PM, Smith P et al. Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and nelfinavir. Am. J. Addict. 13(2), 163–180 (2004).
   PubMed Web of Science ®Google Scholar
• Hendrix CW, Wakeford J, Wire MB et al. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with amprenavir in opioid-dependent subjects. Pharmacotherapy 24(9), 1110–1121 (2004).
   PubMed Web of Science ®Google Scholar
• Friedland G, Andrews L, Schreibman T et al. Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction. AIDS 19(15), 1635–1641 (2005).
   PubMed Web of Science ®Google Scholar
• Cao YJ, Smith PF, Wire MB et al. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir–ritonavir in opioid-dependent subjects. Pharmacotherapy 28(7), 863–874 (2008).
   PubMed Web of Science ®Google Scholar
• Gerber JG, Rosenkranz S, Segal Y et al.; ACTG 401 Study Team. Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401. J. Acquir. Immune Defic. Syndr. 27(2), 153–160 (2001).
   PubMed Web of Science ®Google Scholar
• Shelton MJ, Cloen D, DiFrancesco R et al. The effects of once-daily saquinavir/minidose ritonavir on the pharmacokinetics of methadone. J. Clin. Pharmacol. 44(3), 293–304 (2004).
   PubMed Web of Science ®Google Scholar
• McCance-Katz EF, Farber S, Selwyn PA, O’Connor A. Decrease in methodone levels with nelfinavir mesylate. Am. J. Psychiatry 157(3), 481 (2000).
   PubMed Web of Science ®Google Scholar
• Clarke S, Mulcahy F, Bergin C et al. Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir–ritonavir. Clin. Infect. Dis. 34(8), 1143–1145 (2002).
   PubMed Web of Science ®Google Scholar
• Stevens RC, Rapaport S, Maroldo-Connelly L, Patterson JB, Bertz R. Lack of methadone dose alterations or withdrawal symptoms during therapy with lopinavir/ritonavir. J. Acquir. Immune Defic. Syndr. 33(5), 650–651 (2003).
   PubMed Web of Science ®Google Scholar
• McCance-Katz EF, Moody DE, Smith PF et al. Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir. Clin. Infect. Dis. 43(Suppl. 4), S235–S246 (2006).
   PubMed Web of Science ®Google Scholar
• Kaletra® (lopinavir/ritonavir), product information. Abbott Laboratories, IL, USA (2009).
   Google Scholar
• Tossonian HK, Raffa JD, Grebely J et al. Methadone dosing strategies in HIV-infected injection drug users enrolled in a directly observed therapy program. J. Acquir. Immune Defic. Syndr. 45(3), 324–327 (2007).
   PubMed Web of Science ®Google Scholar
• Aptivus® (tipranavir), product information. Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA (2005).
   Google Scholar
• Sekar V, Tomaka F, Lefebvre E et al. Pharmacokinetic interactions between darunavir/ritonavir and opioid maintenance therapy using methadone or buprenorphine/naloxone. J. Clin. Pharmacol. 51(2), 271–278 (2011).
   PubMed Web of Science ®Google Scholar
• Anderson MS, Mabalot Luk JA, Hanley WD et al. Effect of raltegravir on the pharmacokinetics of methadone. J. Clin. Pharmacol. 50(12), 1461–1466 (2010).
   PubMed Web of Science ®Google Scholar
• Iwamoto M, Wenning LA, Nguyen BY et al. Effects of omeprazole on plasma levels of raltegravir. Clin. Infect. Dis. 48(4), 489–492 (2009).
   PubMed Web of Science ®Google Scholar
• Song I, Mark S, Borland J et al. Dolutegravir has no effect on pharmacokinetics of methadone or oral contraceptives with norgestimate and ethinyl estradiol. Abstract 535. Presented at: 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA, USA, 3–6 March 2013.
   Google Scholar
• CSAT. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Department of Health and Human Services, Rockville, MD, USA (2004).
   Google Scholar
• Altice FL, Bruce RD, Lucas GM et al.; BHIVES Collaborative. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J. Acquir. Immune Defic. Syndr. 56(Suppl. 1), S22–S32 (2011).
   PubMed Web of Science ®Google Scholar
• Baker J, Rainey PM, Moody DE, Morse GD, Ma Q, McCance-Katz EF. Interactions between buprenorphine and antiretrovirals: nucleos(t)ide reverse transcriptase inhibitors (NRTI) didanosine, lamivudine, and tenofovir. Am. J. Addict. 19(1), 17–29 (2010).
   PubMed Web of Science ®Google Scholar
• Boas RA, Villiger JW. Clinical actions of fentanyl and buprenorphine. The significance of receptor binding. Br. J. Anaesth. 57(2), 192–196 (1985).
   PubMed Web of Science ®Google Scholar
• Bruce RD, Altice FL. Three case reports of a clinical pharmacokinetic interaction with buprenorphine and atazanavir plus ritonavir. AIDS 20(5), 783–784 (2006).
   PubMed Web of Science ®Google Scholar
• McCance-Katz EF, Moody DE, Morse GD et al. Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. Drug Alcohol Depend. 91(2–3), 269–278 (2007).
   PubMed Web of Science ®Google Scholar
• Vergara-Rodriguez P, Tozzi MJ, Botsko M et al.; BHIVES Collaborative. Hepatic safety and lack of antiretroviral interactions with buprenorphine/naloxone in HIV-infected opioid-dependent patients. J. Acquir. Immune Defic. Syndr. 56(Suppl. 1), S62–S67 (2011).
   PubMed Web of Science ®Google Scholar
• Bruce RD. Additional explanation for lack of pharmacodynamic interaction between atazanavir and buprenorphine reported by Vergara-Rodriquez et al. J. Acquir. Immune Defic. Syndr. 58(4), e112; author reply e112–e113 (2011).
   Google Scholar
• Reyataz®, product information. Bristol-Myers Sqibb, NY, USA (2011).
   Google Scholar
• Bruce RD, Altice FL, Moody DE et al. Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir. J. Acquir. Immune Defic. Syndr. 54(5), 511–514 (2010).
   PubMed Web of Science ®Google Scholar
• Gruber VA, Rainey PM, Moody DE et al. Interactions between buprenorphine and the protease inhibitors darunavir-ritonavir and fosamprenavir-ritonavir. Clin. Infect. Dis. 54(3), 414–423 (2012).
   PubMed Web of Science ®Google Scholar
• Bruce RD, Altice FL, Moody DE et al. Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone. Drug Alcohol Depend. 105(3), 234–239 (2009).
   PubMed Web of Science ®Google Scholar
• Bruce RD, Moody DE, Fang WB, Chodkowski D, Andrews L, Friedland GH. Tipranavir/ritonavir induction of buprenorphine glucuronide metabolism in HIV-negative subjects chronically receiving buprenorphine/naloxone. Am. J. Drug Alcohol Abuse 37(4), 224–228 (2011).
   PubMed Web of Science ®Google Scholar
• Bruce R, Moody D, Chodkowski D et al. Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir. Abstract MOPE176. Presented at: 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. Rome, Italy, 17–20 July 2011.
   Google Scholar
• Berk SI, Litwin AH, Arnsten JH, Du E, Soloway I, Gourevitch MN. Effects of pegylated interferon α-2b on the pharmacokinetic and pharmacodynamic properties of methadone: a prospective, nonrandomized, crossover study in patients coinfected with hepatitis C and HIV receiving methadone maintenance treatment. Clin. Ther. 29(1), 131–138 (2007).
   PubMed Web of Science ®Google Scholar
• Gupta SK, Sellers E, Somoza E, Angles L, Kolz K, Cutler DL. The effect of multiple doses of peginterferon α-2b on the steady-state pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy. J. Clin. Pharmacol. 47(5), 604–612 (2007).
   PubMed Web of Science ®Google Scholar
• Sulkowski M, Wright T, Rossi S et al. Peginterferon α-2a does not alter the pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy. Clin. Pharmacol. Ther. 77(3), 214–224 (2005).
   PubMed Web of Science ®Google Scholar
• Kempf DJ, Klein C, Chen HJ et al. Pharmacokinetic enhancement of the hepatitis C virus protease inhibitors VX-950 and SCH 503034 by co-dosing with ritonavir. Antivir. Chem. Chemother. 18(3), 163–167 (2007).
   PubMedGoogle Scholar
• Ghosal A, Yuan Y, Tong W et al. Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor. Drug Metab. Dispos. 39(3), 510–521 (2011).
   PubMed Web of Science ®Google Scholar
• Van Heeskwijk R, Vandevoorde A, Verboven P et al. The pharmacokinetic interaction between methadone and the investigational HCV protease inhibitor telaprevir. Abstract 654. Presented at: 46th Annual Meeting of the European Association for the Study of the Liver. Berlin, Germany, 30 March – 3 April 2011.
   Google Scholar
• Luo X, Trevejo J, van Heeswijk RP, Smith F, Garg V. Effect of telaprevir on the pharmacokinetics of buprenorphine in volunteers on stable buprenorphine/naloxone maintenance therapy. Antimicrob. Agents Chemother. 56(7), 3641–3647 (2012).
   PubMed Web of Science ®Google Scholar
• Hulskotte E, Feng HP, Bruce RD et al. Pharmacokinetic interactions between HCV protease inhibitor boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy. Presented at: 7th International Workshop on Clinical Pharmacology of Hepatitis Therapy. Cambridge, MA, USA, 27–28 June 2012.
   Google Scholar
• Denning J, Cornpropst MT, Clemons D et al. Lack of effect of the nucleotide analog polymerase inhibitor PSI-7977 on methadone PK and PD. Presented at: American Association for the Study of Liver Diseases Annual Meeting. San Francisco, CA, USA, 6–9 November 2011.
   Google Scholar
• Ouwerkerk-Mahadevan O, Beaumont-Mauviel M, Peeters M, Akuma SH, Sekar V. The pharmacokinetic interaction between the investigational NS3/4A HCV protease inhibitor TMC435 and methadone. Presented at: American Association for the Study of Liver Diseases Annual Meeting. Boston, MA, USA, 9–13 November 2012.
   Google Scholar
• Handelsman L, Cochrane KJ, Aronson MJ, Ness R, Rubinstein KJ, Kanof PD. Two new rating scales for opiate withdrawal. Am. J. Drug Alcohol Abuse 13(3), 293–308 (1987).
   PubMed Web of Science ®Google Scholar
• Saber-Tehrani AS, Bruce RD, Altice FL. Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence. Am. J. Drug Alcohol Abuse 37(1), 1–11 (2011).
   PubMed Web of Science ®Google Scholar
• Cobb MN, Desai J, Brown LS Jr, Zannikos PN, Rainey PM. The effect of fluconazole on the clinical pharmacokinetics of methadone. Clin. Pharmacol. Ther. 63(6), 655–662 (1998).
   PubMed Web of Science ®Google Scholar
• Ehret GB, Voide C, Gex-Fabry M et al. Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors. Arch. Intern. Med. 166(12), 1280–1287 (2006).
   PubMed Web of Science ®Google Scholar